Sanziana A. Roman

Sanziana A. Roman

Auto-generated profile, based on publicly available information

Sanziana A. Roman

Univ Calif San Francisco UCSF, Dept Surg, San Francisco, CA USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
JKJina Kim
Jina Kim
JGJessica E. Gosnell
Jessica E. Gosnell
SRSanziana A. Roman
Sanziana A. Roman

1 April 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
EREwa Ruel
Ewa Ruel
STSamantha Thomas
Samantha Thomas
MDMichaela Dinan
Michaela Dinan
JPJennifer M. Perkins
Jennifer M. Perkins
SRSanziana A. Roman
Sanziana A. Roman
JSJulie Ann Sosa
Julie Ann Sosa
Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The long-term prognosis is generally excellent. Due to a paucity of data, debate exists regarding the benefit of adjuvant radioactive iodine therapy (RAI) for intermediate-risk patients. The objective of the study was to examine the impact of RAI on overall survival in intermediate-risk PTC patients. Adult patients with intermediate-risk PTC who underwent total thyroidectomy with/without RAI in the National Cancer Database, 1998-2006, participated in the study. Intermediate-risk patients, as defined by American Thyroid Association risk and American Joint Commission on Cancer disease stage T3, N0, M0 or Mx, and T1-3, N1, M0, or Mx were included in the study. Patients with aggressive variants and multiple primaries were excluded. Overall survival (OS) for patients treated with and without RAI using univariate and multivariate regression analyses was measured. A total of 21 870 patients were included; 15 418 (70.5%) received RAI and 6452 (29.5%) did not. Mean follow-up was 6 years, with the longest follow-up of 14 years. In an unadjusted analysis, RAI was associated with improved OS in all patients (P < .001) as well as in a subgroup analysis among patients younger than 45 years (n = 12 612, P = .002) and 65 years old and older (median OS 140 vs 128 mo, n = 2122, P = .008). After a multivariate adjustment for demographic and clinical factors, RAI was associated with a 29% reduction in the risk of death, with a hazard risk 0.71 (95% confidence interval 0.62-0.82, P < .001). For age younger than 45 years, RAI was associated with a 36% reduction in risk of death, with a hazard risk 0.64 (95% confidence interval 0.45- 0.92, P = .016). This is the first nationally representative study of intermediate-risk PTC patients and RAI therapy demonstrating an association of RAI with improved overall survival. We recommend that this patient group should be considered for RAI therapy.

20 May 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
LGLauren Gratian
Lauren Gratian
JPJohn Pura
John Pura
MDMichaela Dinan
Michaela Dinan
SRSanziana Roman
Sanziana Roman
SRShelby Reed
Shelby Reed
JSJulie Ann Sosa
Julie Ann Sosa

1 January 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
MAMohamed Abdelgadir Adam
Mohamed Abdelgadir Adam
JPJohn Pura
John Pura
PGPaolo Goffredo
Paolo Goffredo
MDMichaela A. Dinan
Michaela A. Dinan
THTerry Hyslop
Terry Hyslop
JSJulie A. Sosa
Julie A. Sosa
Context: Papillary thyroid cancer (PTC) patients 1.0 cm, regardless of age. Objective: Our objective was to examine the impact of extent of surgery on overall survival (OS) in patients <45 years old with stage I PTC of 1.1 to 4.0 cm. Design, Setting, and Patients: Adult patients <45 years of age undergoing surgery for stage I PTC were identified from the National Cancer Data Base (NCDB, 1998–2006) and the Surveillance, Epidemiology, and End Results dataset (SEER, 1988–2006). Main Outcome Measure: Multivariable modeling was used to compare OS for patients undergoing total thyroidectomy vs lobectomy. Results: In total, 29 522 patients in NCDB (3151 lobectomy, 26 371 total thyroidectomy) and 13 510 in SEER (1379 lobectomy, 12 131 total thyroidectomy) were included. Compared with patients undergoing lobectomy, patients having total thyroidectomy more often had extrathyroidal and lymph node disease. At 14 years, unadjusted OS was equivalent between total thyroidectomy and lobectomy in both databases. After adjustment, OS was similar for total thyroidectomy compared with lobectomy across all patients with tumors of 1.1 to 4.0 cm (NCDB: hazard ratio = 1.45 [confidence interval = 0.88–2.51], P = 0.19; SEER: 0.95 (0.70–1.29), P = 0.75) and when stratified by tumor size: 1.1 to 2.0 cm (NCDB: 1.12 [0.50–2.51], P = 0.78; SEER: 0.95 [0.56–1.62], P = 0.86) and 2.1 to 4.0 cm (NCDB: 1.93 [0.88–4.23], P = 0.10; SEER: 0.94 [0.60–1.49], P = 0.80). Conclusions: After adjusting for patient and clinical characteristics, total thyroidectomy compared with thyroid lobectomy was not associated with improved survival for patients <45 years of age with stage I PTC of 1.1 to 4.0 cm. Additional clinical and pathologic factors should be considered when choosing extent of resection.

11 December 2012 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
PGPaolo Goffredo
Paolo Goffredo
JSJulie A. Sosa
Julie A. Sosa
SRSanziana A. Roman
Sanziana A. Roman

1 October 2013 in Thyroid®
Verified
Journal Article
Closed access
EKEric J. Kuo
Eric J. Kuo
PGPaolo Goffredo
Paolo Goffredo
JSJulie A. Sosa
Julie A. Sosa
SRSanziana A. Roman
Sanziana A. Roman
Background: Tall cell variant (TCV) and diffuse sclerosing variant (DSV) of papillary thyroid cancer are aggressive subtypes, for which tumors ≤1 cm have not been exclusively studied. Methods: The SEER database (1988–2009) was used to compare characteristics of TCV ≤1 cm (mTCV) and DSV ≤1 cm (mDSV) with classic papillary thyroid microcarcinoma (mPTC). Survival was analyzed with the Kaplan–Meier method and log-rank test, and risk factors for nodal metastases with chi-square analysis and binary logistic regression. Results: There were 97 mTCV, 90 mDSV, and 18,260 mPTC patients. mTCV incidence increased by 79.9% ( p =0.153) over the study period, while mDSV incidence decreased by 10.3% ( p =0.315). Compared to classic mPTC, mTCV tended to be larger on average (7.1 mm vs. 5.3 mm, p <0.001), with higher rates of multifocality (47.2% vs. 34.0% respectively, p =0.018) and lymph-node examination (63.9% vs. 39.2% respectively, p <0.001), while in mDSV, nodal metastases were more frequent (57.1% vs. 33.1% respectively, p =0.007). Both aggressive variants had higher rates of extrathyroidal extension (27.8% mTCV vs. 13.3% mDSV vs. 6.1% mPTC, p <0.001). Aggressive variants also received radioactive iodine more frequently (39.2% mTCV vs. 40.0% mDSV vs. 29.1% mPTC, p 7 mm (odds ratio (OR) 4.4 [CI 1.5–13.6]) and nodal metastasis with multifocality (OR 5.4 [CI 1.3–23.4]) and extrathyroidal extension (OR 5.8 [CI 1.3–25.4]). No statistically significant predictors of extrathyroidal extension or nodal metastasis in mDSV were observed. Conclusions: Aggressive variants of mPTC tend to exhibit more aggressive pathologic characteristics than classic mPTC, but survival appears to be similar. Treatment with total thyroidectomy and central lymphadenectomy may be warranted if the diagnosis can be made pre- or intraoperatively.